Healthcare -
Biotechnology - NASDAQ - US
$ 2.68
0 %
$ 77.7 M
Market Cap
-0.05
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aerovate Therapeutics, Inc.
| Net Income | -69.6 M |
| Depreciation & Amortization | 282 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | -9 M |
| Others | -13.2 M |
| Free Cash Flow | -71.2 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (69.6) | (75.5) | (51.5) | (23.0) | (9.6) | (3.3) |
| Depreciation & Amortization | 0.3 | 96 K | 68 K | 15 K | 1 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 11.3 | 11.9 | 5.5 | 2.0 | 58 K | 0 |
| Other Operating Activities | (4.2) | (3.1) | (0.9) | 16 K | 0.7 | (0.4) |
| Change in Working Capital | (9.0) | 9.8 | 7.8 | (6.5) | 1.0 | 0.5 |
| Cash From Operations | (71.2) | (56.8) | (39.1) | (27.4) | (7.9) | (2.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | (0.1) | (0.2) | (0.2) | 0 | 0 |
| Other Items | 56.0 | 12.0 | 7.1 | (113.3) | 0 | 0 |
| Cash From Investing Activities | 56.0 | 11.9 | 6.9 | (113.4) | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 2.5 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.5 | 2.2 | 0.4 | 63.5 | 12.8 | 2.5 |
| Cash From Financing Activities | 25.4 | 46.0 | 0.4 | 190.5 | 8.9 | 2.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 10.3 | 1.1 | (31.8) | 49.6 | 1.1 | (0.3) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (71.2) | (56.9) | (39.3) | (27.6) | (7.9) | (2.8) |